| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 681 | 916 | 852 | 895 | 935 | 1,216 | 1,132 | 1,109 | 1,168 | 931 | 1,110 | 1,000 | 824 | 1,246 | 1,427 | 1,583 | 1,580 | 1,453 | 1,466 | 1,443 | 1,469 | 1,563 | 1,571 |
| Expenses | 395 | 472 | 534 | 595 | 560 | 718 | 704 | 714 | 755 | 587 | 748 | 649 | 673 | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 |
| EBITDA | 286 | 445 | 318 | 299 | 375 | 498 | 428 | 395 | 414 | 344 | 363 | 351 | 151 | 332 | 377 | 394 | 401 | 316 | 357 | 418 | 392 | 425 | 398 |
| Operating Profit % | 38 % | 47 % | 36 % | 31 % | 37 % | 38 % | 35 % | 33 % | 32 % | 32 % | 28 % | 31 % | 14 % | 24 % | 24 % | 23 % | 23 % | 19 % | 21 % | 26 % | 24 % | 24 % | 21 % |
| Depreciation | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 28 | 31 | 35 | 37 | 38 | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 |
| Profit Before Tax | 262 | 420 | 293 | 273 | 349 | 472 | 401 | 366 | 381 | 309 | 324 | 311 | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 |
| Tax | 67 | 106 | 74 | 69 | 89 | 121 | 99 | 93 | 95 | 79 | 83 | 79 | 33 | 67 | 96 | 91 | 106 | 75 | 93 | 95 | 102 | 97 | 100 |
| Net Profit | 195 | 314 | 219 | 204 | 260 | 351 | 302 | 273 | 286 | 229 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 216 | 184 |
| EPS in ₹ | 12.57 | 20.24 | 14.12 | 12.83 | 15.93 | 21.41 | 18.37 | 16.62 | 17.40 | 13.93 | 14.65 | 14.08 | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 |
Gland Pharma
Gland Pharma
1,680.60
-14.20
(-0.84%)
Market Cap
27,688.96 Cr
PE Ratio
35.42
Volume
93,457.00
Day High - Low
1,700.00 - 1,672.30
52W High-Low
2,131.00 - 1,277.80
Key Fundamentals
Market Cap
27,688.96 Cr
EPS
42.40
PE Ratio
35.42
PB Ratio
2.93
Book Value
580.41
EBITDA
1,482.50
Dividend Yield
1.06 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
7.63
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from13 analysts
Actual
Company News
View All News
Gland Pharma Limited announces board meeting on January 28, 2026 to approve Q3FY26 unaudited financial results for quarter ended December 31, 2025. Trading window reopens January 31.
Gland Pharma receives US FDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% as over-the-counter medication, expanding its ophthalmic product portfolio in American market.
Gland Pharma Limited receives USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), therapeutically equivalent to Alcon's Pataday Once Daily Relief for treating ocular itching.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,729.90 | #1 4,15,060.96 | 40.31 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 44.32 | |
6,616.50 | 1,75,647.29 | 70.47 | 9,712.00 | 18.67 | 2,191 | 35.10 | 60.68 | |
3,963.40 | 1,34,139.47 | 63.66 | 11,539.40 | 6.99 | 1,911 | 30.46 | 61.70 | |
1,465.70 | 1,18,395.11 | 21.71 | 28,409.50 | 7.12 | 5,291 | 3.71 | 38.82 | |
1,210.10 | 1,00,998.62 | #1 17.57 | 33,741.20 | 16.73 | 5,725 | -0.38 | 31.03 | |
2,182.20 | 99,682.64 | 23.02 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 63.83 | |
2,200.80 | 90,850.14 | 52.52 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 48.57 | |
894.90 | 90,047.88 | 18.16 | 23,511.00 | 18.55 | 4,615 | 34.60 | 35.88 | |
1,198.70 | 69,620.69 | 20.49 | 32,345.60 | 9.43 | 3,484 | 3.81 | 48.80 | |
5,799.00 | 69,335.74 | 28.76 | 13,458.30 | 3.70 | 2,216 | 10.98 | 63.14 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-0.08 %
Net Income Growth
-9.58 %
Cash Flow Change
-8.23 %
ROE
-13.79 %
ROCE
-8.55 %
EBITDA Margin (Avg.)
-1.28 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 |
| Fixed Assets | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 |
| Current Assets | 2,846 | 5,124 | 5,852 | 6,901 | 5,645 | 6,783 |
| Capital Work in Progress | 189 | 338 | 191 | 177 | 238 | 151 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 |
| Other Assets | 2,930 | 5,204 | 5,986 | 7,030 | 6,477 | 6,927 |
| Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 |
| Current Liabilities | 359 | 513 | 582 | 729 | 1,398 | 1,565 |
| Non Current Liabilities | 81 | 80 | 94 | 90 | 539 | 509 |
| Total Equity | 3,646 | 5,903 | 7,158 | 7,959 | 8,724 | 9,151 |
| Reserve & Surplus | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 |
| Share Capital | 16 | 16 | 16 | 17 | 17 | 17 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 |
| Investing Activities | -761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 |
| Operating Activities | 701 | 605 | 791 | 364 | 997 | 915 |
| Financing Activities | -7 | 1,239 | 35 | 15 | -799 | -434 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 58.25 % | 58.14 % | 58.02 % | 58.00 % | 58.00 % | 57.87 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 4.91 % | 0.00 % | 3.59 % | 6.88 % | 4.47 % | 5.04 % | 6.90 % | 7.39 % | 7.91 % |
| DIIs | 10.69 % | 11.57 % | 11.39 % | 11.21 % | 11.94 % | 16.71 % | 20.58 % | 23.13 % | 23.23 % | 23.38 % | 22.45 % | 23.14 % | 25.23 % | 32.83 % | 35.37 % | 34.80 % | 33.27 % | 32.85 % | 32.64 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.30 % | 3.72 % | 3.77 % | 3.58 % | 3.69 % | 3.70 % | 3.77 % | 4.02 % | 4.26 % | 5.60 % | 4.52 % | 3.79 % | 3.28 % | 3.33 % | 3.28 % | 3.30 % | 2.99 % | 2.91 % | 2.57 % |
| Others | 27.76 % | 26.58 % | 26.81 % | 27.21 % | 26.37 % | 21.71 % | 17.78 % | 14.98 % | 14.64 % | 13.16 % | 10.27 % | 15.22 % | 10.04 % | 5.12 % | 5.04 % | 5.04 % | 5.01 % | 5.02 % | 5.06 % |
| No of Share Holders | 84,467 | 98,203 | 1,09,326 | 1,09,097 | 1,09,098 | 1,17,339 | 1,27,879 | 1,48,469 | 1,50,578 | 1,81,747 | 1,61,627 | 1,36,021 | 1,22,375 | 1,22,665 | 1,22,358 | 1,21,075 | 1,13,788 | 1,10,671 | 97,151 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20 | 18 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26 | 1.07 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Jan 2026 |  Quarterly Result Announcement | NA | 28 Jan 2026 | 1,698.95 | 1,680.60 |
| 16 Aug 2024 |  Dividend | ₹ 20.00 /share | 16 Aug 2024 | 1,800.25 | 1,958.25 |
| 30 Aug 2024 |  Annual General Meeting | NA | 30 Aug 2024 | 1,800.25 | 1,849.00 |
| 04 Nov 2024 | Quarterly Result Announcement | NA | 04 Nov 2024 | 1,675.30 | 1,644.85 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 1,672.75 | 1,530.45 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 1,418.75 | 1,484.15 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 2,000.80 | 1,982.80 |
| 14 Aug 2025 | Dividend | ₹ 18.00 /share | 14 Aug 2025 | 1,484.15 | 1,950.30 |
| 28 Aug 2025 | Annual General Meeting | NA | 28 Aug 2025 | 1,484.15 | 1,928.25 |
| 03 Nov 2025 | Quarterly Result Announcement | NA | 03 Nov 2025 | 1,917.60 | 1,928.90 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2 days ago
2 days agoBoard Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 20252 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
4 days agoClosure of Trading WindowDec 26, 2025
Dec 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 12, 2025
Dec 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 11, 2025
Dec 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 08, 2025
Dec 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 03, 2025
Nov 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 03, 2025
Nov 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 03, 2025
Nov 03, 2025Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 03, 2025
Nov 03, 2025Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 03, 2025
Nov 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 17, 2025
Oct 17, 2025Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Oct 17, 2025
Oct 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Oct 14, 2025Closure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2025
Sep 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 28, 2025
Aug 28, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 28, 2025
Aug 28, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Aug 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 18, 2025
Aug 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 11, 2025
Aug 11, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 05, 2025
Aug 05, 2025Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter Ended June 30 2025Aug 05, 2025
Aug 05, 2025Unaudited Financial Results For The Quarter Ended June 30 2025Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Rumour verification - Regulation 30(11)Aug 01, 2025
Aug 01, 2025Clarification sought from Gland Pharma LtdAug 01, 2025
Aug 01, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 31, 2025
Jul 31, 2025Notice Of 47Th AGM Of Gland Pharma LimitedJul 31, 2025
Jul 31, 2025Reg. 34 (1) Annual Report.Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Jul 21, 2025Board Meeting Intimation for Declaration Of Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Jul 21, 2025
Jul 21, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 42.81
ATR(14)
Less Volatile 43.50
STOCH(9,6)
Neutral 61.79
STOCH RSI(14)
Neutral 71.59
MACD(12,26)
Bullish 7.28
ADX(14)
Weak Trend 21.58
UO(9)
Bearish 46.20
ROC(12)
Downtrend And Accelerating -0.43
WillR(14)
Neutral -68.28
About Gland Pharma
Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs....more
Listing Date
20 Nov, 2020(5 Years,
22 days)
Website
Chairperson NameSRINIVAS SADU
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
